IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

A REVIEW OF FORMULATION OF SUSTAINED RELEASE SOLID LIPID MICROPARTICLES OF METFORMIN

***Nitish Choudhary[1] , Hans Raj[2], Maneesh Banyal[3], Jyoti Gupta[4]**

*Nitish Choudhary, Student of Masters of Pharmaceutics, IEC University, Baddi.
Hans Raj , Associate Proffessor , school of Pharmacy , IEC University , Baddi.
Maneesh Banyal , Assistant Proffessor , School of Pharmacy , IEC University , Baddi.
Jyoti Gupta , Associate Proffessor , Head of Department , IEC University , Baddi.

Abstract:

Diabetes mellitus is a long-term metabolic disorder that needs good and long-lasting control of blood sugar levels. Metformin is a first-line treatment for type 2 diabetes mellitus (T2DM), but it has some problems, such as a short half-life, low bioavailability, and gastrointestinal side effects that require frequent dosing. To solve these problems, scientists have created sustained-release solid lipid microparticles (SLMs) as a new way to deliver drugs.

SLMs are made of lipids that break down naturally and help drugs stay stable, become more available to the body, and be released in a controlled way. This means that the dose can be given less often and the side effects are less severe. Choosing the right lipids, surfactants, and stabilizers is an important part of the formulation. Stearic acid and glyceryl monostearate are two lipids that are often used. Different methods of preparation, like high-pressure homogenization and solvent evaporation, have been looked into to find the best particle size, encapsulation efficiency, and release kinetics.

Preclinical studies, both in vitro and in vivo, show that SLMs could be useful for extending drug release and improving therapeutic outcomes. SLM-based metformin formulations have the potential to improve diabetes management, but they are difficult to make on a large scale and meet regulatory requirements. Future improvements in lipid-based nanocarriers and personalized medicine could make this drug delivery system even better, making it easier for patients to follow their treatment plans and keep their blood sugar levels stable.

Introduction:

Diabetes mellitus is a long-term metabolic disorder that causes high blood sugar levels because of problems with insulin secretion, insulin action, or both. Metformin is a common first-line treatment for type 2 diabetes mellitus (T2DM) because it lowers blood sugar levels by lowering the amount of glucose produced by the liver and making insulin work better. Metformin works well as a medicine, but it has some problems. Its half-life is only about 4 to 6 hours, it has poor bioavailability (50 to 60%), and it can cause gastrointestinal side effects, which means that patients have to take it often and may not follow the instructions. To deal with these problems, there has been a lot of interest in creating sustained-release drug delivery systems, especially solid lipid microparticles (SLMs).

Solid lipid microparticles are a cutting-edge way to deliver drugs. They are made up of lipids that break down and are safe for the body. They are better than regular dosage forms because they make drugs more stable, release them more slowly, and make them more available to the body. SLMs are a good way to deliver drugs over a long period of time because they trap the drug in lipid matrices, which controls the release of the drug. This method lowers the number of doses needed, increases the effectiveness of the treatment, and lowers the risk of systemic side effects, all of which make patients more likely to stick with their treatment.

In order to achieve the best possible drug encapsulation and controlled release, lipid excipients, stabilizers, and surfactants must be carefully chosen when creating sustained-release SLMs of metformin. Since the physicochemical characteristics of lipids affect drug diffusion and degradation rates, the composition of lipids is a critical factor in determining drug release kinetics. Because they offer structural integrity and sustained-release qualities, stearic acid, glyceryl monostearate, and tristearin are frequently used lipids in SLM formulations. In order to stabilize the formulation and stop particle aggregation, surfactants like Poloxamers and Tween 80 are also added.

Several formulation methods have been investigated in order to create SLMs with controlled drug release profiles, high drug loading efficiency, and a desired particle size. These methods include solvent evaporation, high-pressure homogenization, and melt emulsification. The physicochemical characteristics of SLMs, such as particle size distribution, surface morphology, zeta potential, and encapsulation efficiency, are optimized by these techniques because they have a major impact on drug release kinetics.

Both in vitro and in vivo studies are used to assess the efficacy of sustained-release SLMs of metformin in extending drug release and enhancing therapeutic results. Using dissolution techniques, in vitro drug release studies aid in evaluating the mechanism of drug diffusion and release kinetics. Stability tests are also carried out to guarantee formulation integrity in a range of storage scenarios. The pharmacokinetic characteristics, bioavailability, and therapeutic potential of the prepared SLMs in animal models or human subjects are further confirmed by in vivo investigations.

One promising strategy to improve medication delivery and therapeutic efficacy in the treatment of diabetes is the creation of sustained-release solid lipid microparticles for metformin. SLMs present a viable approach to enhance patient compliance, reduce side effects, and guarantee improved glycemic control by overcoming the drawbacks of traditional metformin formulations. Millions of people with diabetes worldwide could benefit from the successful commercialization of SLM-based sustained-release metformin formulations, which could be made possible by additional research and formulation strategy optimization.

NEED FOR SUSTAINED RELEASE FORMULATION OF METFORMIN:

1. Limitation of conventional metformin therapy

Although metformin is a first-line treatment for type 2 diabetes mellitus (T2DM), there are a number of issues with its traditional immediate-release (IR) formulations.

- Frequent dosing is necessary due to the short biological half-life (approximately 4-6 hours) (2–3 times per day).
- Poor patient compliance results from a high dose requirement (500–2000 mg/day).
- Side effects related to the gastrointestinal system (GI): causes discomfort, bloating, diarrhea, and nausea, which can cause some patients to stop taking their medication.
- Poor intestinal absorption results in low bioavailability (~50%).
- Lactic acidosis risk: Although uncommon, this risk rises with increased dosage. Sustained release (SR) formulations have been created to get around these problems.

2. Advantages of sustained release metformin formulation

In order to improve therapeutic results, sustained release formulations alter the drug release profile. Enhanced Patient Compliance is one of their main benefits.

- Improves adherence by lowering the frequency of dosing to once daily.
- Reduces variations in blood sugar levels.

Decreased adverse effects on the gastrointestinal tract

- Local gastrointestinal irritation is reduced by gradual drug release.
- Prevents abrupt increases in focus, which lessens diarrhea and nausea. Improved Glycemic Management
- Stable blood glucose regulation is provided by sustained drug levels in plasma.
- As opposed to IR formulations, it lessens postprandial glucose spikes. Increased Bioavailability
- Prevents drug loss because of the liver's and stomach's quick metabolism.
- Long-term, optimal absorption in the small intestine. Reduced Lactic Acidosis Risk
- Lower peak concentrations are guaranteed by controlled release, which lowers the risk.

3. Solid lipid microparticles SLMs as a sustained release approach

For Metformin SR formulations, SLMs present a promising nanotechnology-based solution because of: • Controlled Drug Release: Offers extended absorption and therapeutic effect.

- Biodegradability: Lipids are non-toxic and biocompatible.
- Better Drug Stability: Prevents Metformin from degrading in acidic environments.
- Improved Drug Encapsulation: Metformin is effectively trapped by lipid matrices for long-lasting effects.

4. commercial sustained release metformin products

- Glucophage XR(Extended release)
- Fortamet® (Osmotic-controlled release)
- Glumetza® (Gastro-retentive SR)

Role of Solid Microparticles (SLMs) in Drug Delivery

1. Introduction to solid lipid microparticles (SLMs)

The drug is integrated into a solid lipid matrix that stays solid at body and room temperatures in Solid Lipid Microparticles (SLMs), a lipid-based drug delivery system. They are a promising substitute for traditional drug delivery methods, especially when it comes to the controlled and prolonged release of hydrophilic and lipophilic medications.

2. Advantages of SLMs in Drug Delivery

Because of their controlled release characteristics and biocompatibility, SLMs are favored over traditional carriers (such as

polymeric nanoparticles and emulsions). Among the main benefits are:

❖ Long-Term and Regulated Drug Release

SLMs are appropriate for chronic conditions like diabetes, heart disease, and cancer because they prolong drug release, lowering the frequency of administration.

❖ Increased Bioavailability

- Lipid-based carriers enhance drug absorption and solubility, especially for medications that are not very soluble in water.
- Prevents the gastrointestinal (GI) tract from breaking down labile medications.

❖ Reduced Intestinal Adverse Reactions

- By acting as a barrier, lipids lessen the irritation that medications like metformin cause to the stomach.

❖ Enhanced Stability of Drugs

- The lipid matrix extends shelf life by preventing oxidation and degradation. Safe and biodegradable
- The lipids utilized in SLMs are non-toxic and biodegradable due to their physiological tolerance and natural metabolism.

3. Mechanism of Drug Release form SLMs

There are several ways that a drug can be released from SLMs:

- Diffusion-Controlled Release: Drug molecules move through the lipid matrix gradually.
- Erosion-Controlled Release: The drug is released gradually as the lipid matrix deteriorates.
- Diffusion and Erosion Together : To ensure sustained drug action, the release is regulated by both diffusion and erosion.

4. Formulation of SLMs of Sustained Drug release

SLMs are made using a variety of methods to regulate the release profile, drug encapsulation, and particle size:

1. High Shear Homogenization: High pressure is used to mix medications and lipids.
2. Solvent Evaporation Method: To create microparticles, a drug-lipid solution is evaporated.
3. Microemulsion Technique: Precipitation occurs after a microemulsion forms.
4. Spray drying: This method is used in the pharmaceutical industry to increase production scale.

5. Evaluation of SLM-Based Drug Delivery Systems

(a) Particle Size and Morphology: Using Scanning Electron Microscopy (SEM), Transmission Electron Microscopy (TEM), or Dynamic Light Scattering (DLS), this method evaluates the effectiveness of SLMs as a drug delivery system.

(b) Encapsulation Efficiency (%): Indicates the amount of drug that is successfully incorporated.

(c) In-vitro Drug Release Studies: To examine patterns of controlled and prolonged release.

(d) Zeta Potential Analysis: Assesses stability in a solution.

(e) Thermal and Structural Analysis: To verify stability and crystallinity, X-ray diffraction (XRD) and differential scanning calorimetry (DSC) are used.

6. Appilication of SLMs imDrug Delivery

- Oral drug delivery is used to treat cardiovascular, cancer, and diabetes.
- Pulmonary Drug Delivery: Used to treat asthma and lung infections.
- Topical and Transdermal Drug Delivery: For long-term skin absorption.
- Targeted Drug Delivery: Drugs can be delivered to particular tissues or organs using modified SLMs.

7. Solid Lipid Microparticles for Metformin Sustained Release SLMs are especially advantageous for metformin because:

- They decrease the frequency of doses (from several daily doses to one daily dose) by prolonging drug release.
- Reduces stomach discomfort, which improves Metformin's tolerability.
- Improves absorption and bioavailability in the small intestine.

In studies on diabetes treatment, metformin-loaded SLMs have demonstrated better glycemic control and fewer adverse effects.

8. Challenges and future perspective

Even though SLMs have many benefits, there are still certain difficulties:

- Lipid crystallization results in a low drug loading capacity.
- The pharmaceutical industry faces challenges in scaling up production. During storage, drugs may expel themselves from the lipid matrix.
- Researchers are looking into advanced encapsulation methods, lipid-polymer hybrids, and nanostructured lipid carriers (NLCs) as solutions to these problems.

Merformin:Pharmacokinetics and Challenges

1. Mechanism of Action in Diabetes treatment

Type 2 Diabetes Mellitus (T2DM) is commonly managed with metformin, an oral hypoglycemic medication that is a member of the biguanide class. It mainly functions by:

- Lowering Hepatic Glucose Production – Metformin activates AMP-activated protein kinase (AMPK) to suppress hepatic gluconeogenesis, or glucose production.
- Improving Peripheral Glucose Uptake: This improves glucose utilization by raising insulin sensitivity in muscle and fat tissues.
- Decreasing Intestinal Glucose Absorption: This lowers postprandial blood glucose levels by reducing the gut's absorption of glucose.
- No Effect on Insulin Secretion: Metformin lowers the risk of hypoglycemia by not stimulating insulin secretion, in contrast to sulfonylureas.

Clinical Benefits:

1. Reduces blood sugar levels without resulting in hypoglycemia.
2. Improves long-term glycemic control by lowering insulin resistance.
3. Encourages weight loss or is weight-neutral (unlike sulfonylureas or insulin).
4. Possible cardiovascular advantages (improves lipid profile, lowers oxidative stress, and reduces inflammation).

2. Pharmacokinetics Limitation of Metformin

Conventional Metformin therapy is effective, but it has a number of pharmacokinetic problems that affect its clinical application:

A. Brief biological half-life (four to six hours)

- The kidneys quickly absorb and eliminate metformin.
- To maintain therapeutic levels, several daily doses are needed, two to three times per day.

B. High Dosage Need (500–2000 mg daily)
- Patients require high doses to attain effective plasma concentrations because of its low bioavailability (~50–60%).
- Gastrointestinal (GI) distress is frequently caused by high dosages.

C. GI Side Effects: GI disorders, such as diarrhea, nausea, and vomiting, as well as cramping and bloating in the abdomen, affect up to 30% of patients.
- These adverse effects frequently result in low patient adherence.

D. Inadequate Bioavailability and Absorption
- The small intestine (upper portion of the jejunum) is where metformin is primarily absorbed. It is hydrophilic, or water soluble.
- Limited permeability across the intestinal lining results in incomplete absorption.

E. The Rare but Serious Risk of Lactic Acidosis
- Metformin can build up in kidney disease patients, raising the risk of lactic acidosis, a potentially lethal illness.
- By reducing peak plasma concentrations, sustained-release formulations help reduce this risk.

Justification for Sustained Release (SR) Formulation

Metformin formulations with sustained release (SR) have been created to get around these pharmacokinetic issues.
Benefits of Metformin Sustained Release:

- ❖ Lower Dosing Frequency: Only a once-daily dose is needed to maintain drug levels for 12 to 24 hours.
- ❖ Better absorption in the intestine is ensured by enhanced bioavailability.
- ❖ Reduced GI Side Effects: By preventing high local concentrations in the stomach, gradual drug release lessens irritation.
- ❖ Improved Patient Compliance: Therapy adherence is improved by fewer dosages and fewer side effects.
- ❖ Reduced Risk of Lactic Acidosis: Sharp increases in plasma levels are avoided by controlled release.

Sustained Release Types Formulations for Metformin:
- Extended-release (XR) tablets, such as Fortamet, Glumetza, and Glucophage XR
- Floating tablets called gastro-retentive drug delivery systems (GRDDS) are made to stay in the stomach longer for a slower release.
- Solid Lipid Microparticles (SLMs): These cutting-edge lipid-based delivery vehicles provide regulated drug release.

Solid Lipids Microparticles (SLMs):

1. What are Solid Lipids Microparicles (SLMs)

Lipid-based drug delivery systems known as Solid Lipid Microparticles (SLMs) distribute a medication within a solid lipid matrix that stays solid at body temperature and room temperature. In pharmaceutical formulations, they provide a novel method for controlled and prolonged drug release.

- ❖ Composition:

Solid lipids (such as glyceryl monostearate, tristearin, and stearic acid) and surfactants (such as Poloxamer, Tween 80, and lecithin) are what make up SLMs. They also stabilize the microparticles.
- Metformin is an example of an active pharmaceutical ingredient (API).

SLMs are made to increase the stability, bioavailability, and controlled release of drugs over a long period of time.

2. Advantages of SLMs Over Other Drug Delivery Systems

SLMs are frequently likened to lipid nanoparticles (LNPs), liposomes, and polymeric nanoparticles (PNPs). They differ in the following ways:×☑☒

Parameter	**SLMs**	**Liposomes**	**Polymeric Nanoparticles (PNPS)**	**Lipids Nanoparticles (LNPS)**
Comosition	Solid lipid Matrix	Pohospholipids bilayer	Synthetic Polymers	Solid + liquid lipids
Biocompatibiltity	☒ High	☑ High	☒ May have toxicity issue	☑High
Drug Loading	☑High (hydrophilic & lipohilic drugs)	☒Low for hudrophilic drugs	☑High	☑High
Release Profile	Sustained and Controlled	Rapids Release	Controlled	Sustained release
Stabilty	☑High	☒Low (prone to degradation)	☑High	☑High
Cost & scalability	☑Cost-effective	☒Expensive	☒Expensive	☒Moderate Cost

- SLMs have a higher drug loading capacity and better stability than liposomes.
- They are also less prone to toxicity and are biodegradable and biocompatible than polymeric nanoparticles.
- Lipid nanoparticles (LNPs) use a combination of liquid and solid lipids, whereas SLMs only use solid lipids.

3. Mechanism of Drug Incorporation and Release in SLMs Techniques for Drug Incorporation

Metformin, or any medication, can be added to SLMs in three different ways:

A. The drug is uniformly distributed throughout the lipid matrix in the homogeneous matrix model.

B. The drug is concentrated at the outer shell of the drug-enriched shell model, which results in rapid release.

C. Drug-Enriched Core Model: The drug is kept in the core for long-term release.

The properties of the drug and the formulation method influence the choice of incorporation model.

B. Mechanisms of Drug Release in SLMs

SLMs use these mechanisms to release medications gradually over time:

- Diffusion-Controlled Dissemination

-Ideal for sustained release formulations such as Metformin, the drug gradually diffuses into the surrounding fluid from the lipid matrix.

- Controlled Erosion Release

-The drug is released when the lipid matrix progressively breaks down.

- Diffusion and Erosion Together

-Most frequently found in SLM formulations, it guarantees consistent drug release over a long time.

4. Why Take Metformin with SLMs?

SLMs have several advantages over metformin because of its short half-life and poor bioavailability:

- Sustained Release: This lowers the frequency of doses (once daily as opposed to twice or three times).
- Better Bioavailability: Prevents quick clearance and improves intestinal absorption.
- Decreased GI Side Effects: This lowers the risk of nausea and diarrhea by preventing a high concentration of the drug in the stomach.
- Improved Patient Compliance: Treatment adherence is enhanced by fewer dosages and fewer side effects.

Formulation of Sustained Release Solid Lipid Microparticles (SLMs) for Metformin

In order to formulate metformin-loaded solid lipid microparticles (SLMs), the proper lipid materials must be chosen, a suitable preparation method must be chosen, and drug encapsulation must be optimized for controlled and prolonged drug release. Let's proceed one step at a time.

1. Selection Criteria for Lipids

A. Lipid Types Employed

Because it affects the stability, encapsulation effectiveness, and rate of drug release, the lipid selection is crucial.

Lipid Type	Example	Role in Formulation
Triglycerides	Tristerin, Tripalmitin	Provide a solid matrix for drug entrapment

Fatty Acids	Stearic Acid, Palmitic Acid	Affect microparticle Stability and release
Glycerides	Glyceryl monostearate (GMS), Compritol 888 ATO	Control Drug Stability and Diffusion
Wax-Based Lipids	Carnauba wax, Beeswax	Offer Long-Term Sustained Release

B. Lipids' Impact on Drug Stability and Release

1. Lipids with a higher melting point (tristearin, Compritol 888 ATO) prolong drug release by slowing down drug diffusion.
2. Glyceryl monostearate, or medium-chain glycerides, improve drug solubility and bioavailability.
3. Waxy lipids, such as beeswax and carnauba wax, lessen drug burst release while preserving sustained action.

To get the best slow and steady release profile for metformin, fatty acids and long-chain triglycerides are usually combined.

2 . Preparation Techniques for Metformin-Loaded SLMs

SLMs are made using a variety of manufacturing processes, each of which has an impact on the drug entrapment, release kinetics, and particle size.

A. High Homogenization of Shear Procedure:

- When lipid is melted, metformin is distributed throughout the liquid.
- The mixture is added while being homogenized at a high speed (10,000–25,000 rpm) in an aqueous surfactant solution.
- Solid lipid microparticles are created by cooling the heated emulsion.

Benefits: Easy and economical for large-scale manufacturing, Generates uniformly small microparticles.

The following are drawbacks: Encapsulation efficiency may be lower than other methods, Heat may cause drug degradation.

B. Method of Solvent Evaporation

- Method: • Lipid and metformin are dissolved in an organic solvent (such as ethanol or chloroform).
- A surfactant-containing aqueous phase is used to emulsify the solution.
- Solid lipid microparticles are left behind when the solvent evaporates.

Benefits: Effective drug encapsulation, Fit for medications that are sensitive to heat (low processing temperature).

- Drawbacks: Organic solvent use may be hazardous, Drug stability may be impacted by residual solvent traces.

C. The Microemulsion Method

The procedure involves combining lipids and surfactants to create a microemulsion, which is then diluted with cold water to create solid lipid microparticles.

Benefits: Generates stable, tiny microparticles with excellent drug loading capacity, Organic solvents are not required.

- Drawbacks: Needs careful lipid-surfactant ratio optimization, Difficult to scale up for industrial production.

D. The Method of Spray Drying

The procedure is as follows: • The solvent evaporates, creating dry microparticles; • The lipid- drug dispersion is atomized into hot air.

Benefits: Fastest and most efficient for large-scale production, It creates extremely stable microparticles.

- Drawbacks: Needs costly equipment, High temperatures may degrade drugs.

Encapsulated Efficiency and Drug Loading

A. Elements That Affect Encapsulation Efficiency (EE%)

The amount of Metformin that is effectively trapped inside the lipid microparticles is known as encapsulation efficiency. Better sustained release is indicated by a higher EE%.

.

Factor	Effect on Encapsulation
Lipid Type	Lipids with a higher melting point raise the EE%.
Lipid Drug Ratio	Better encapsulation results from more lipid.
Surfactant Concenteration	Drug leakage may result from using too much surfactant.
Processing temperature	Drug loss may result from higher temperatures

B. Optimization Techniques Scientists optimize:

- Lipid selection (selecting high-melting lipids such as tristearin) to improve drug loading and encapsulation efficiency.

Concentration of surfactant (balancing stability vs. leakage).

- Drug-lipid ratio: more drug is trapped by higher lipid levels.
- Homogenization time and stirring speed (controls microparticle size).

Evaluatioan of Metformin-Loaded Solid Lipid Microparticle (SLMs)

Evaluation of the physicochemical characteristics, drug release behavior, stability, and pharmacokinetic performance of metformin-loaded SLMs is essential after formulation. This guarantees that the formulation satisfies requirements for safety, effectiveness, and quality.

1. Physiochemical Characterization

Drug stability, absorption, and release are influenced by physicochemical characteristics. These are examined using a number of methods:

A. Morphology and Particle Size What makes it significant?

- Better drug absorption is ensured by smaller particles, either nano or microsized.
- Drug diffusion and stability may be impacted by irregular shapes; uniform size guarantees consistent drug release.

o Techniques used:

Technique	Purpose
Scanning Electron Microscopy (SEM)	investigates the shape and surface morphology of microparticles.
Transmission Electron Microscopy	establishes the drug's distribution and internal structure.
Dynamic Light (DLS)	determines the polydispersity index (PDI) and particle size distribution.

B. Surface Charge (Zeta Potential Analysis)

o What makes it significant? Shows that the solution is stable.

Higher charges repel one another, preventing aggregation.

o Method Employed:

The electrical charge on SLMs is measured by zeta potential analysis.

o ±30 mV or higher = Stable formulation .

o Aggregation and instability risk = less than ±20 mV.

C. Investigations of Crystallinity What makes it significant?

- Identifies the crystalline or amorphous form of metformin.

- Better sustained release is achieved by amorphous drugs because they dissolve more quickly.

❖ Techniques used

Techniques	Purpose
X-ray Diffraction (XRD)	Identifies crystalline vs Amorphous nature.
Differential Calorimetry (DSC)	Detects melting points & thermal stability of drug-lipid mixtures.
Fourier Transform Infrared Spectroscopy (FTIR)	Determine drug-lipid interaction & chemical stability

2. In-Vitro Drug Release Studies Goal: Examine the temporal evolution of metformin release from the lipid microparticles.

A. Techniques for Dissolution Testing What makes it significant?

- Simulates how drugs are released in the body.
- Aids in bioavailability prediction. Approach:

1. SLMs are submerged in an intestinal or gastric fluid simulation.
2. Samples are taken out at various intervals (1, 2, 4, 8, and 24 hours).
3. HPLC or UV spectrophotometry are used to measure drug release.

B. Release Kinetics:

What makes it significant?

- Assists in figuring out how the medication is released:
  - Quick release?
  - Extended release?
  - Managed release?

➢ Mathematical Model Used:

Model	Mechanism	Ideal for
Zero-order kinetic	Drug release is constant over time	Perfect sustained release formulation
First-order kinetic	Release rate depend on drug concentration	Concentration-depend formulation
Higuchi Model	Drug diffuses slowly from the lipid matrix	SLM- based formulation
Korsmeyer-Peppas Model	Drug release follows both diffusion and lipid erosion	Most lipid-based drug

3. Stability Studies:

Why Are They Important?

- Guarantees a long shelf life and prevents deterioration over time.

➢ Parameter Tested:

Factor	Effect on SLMs
Temperature (25°C, 40°C)	Drug leakage or lipid melting may result from heat.
Humidity(60-75% RH)	Particle aggregation may result from excessive moisture.
Light Exposure	The drug or lipid matrix may be weakened by UV light.

How Do You Do It?

- SLMs are kept for three to six months in various storage settings.

- Regular testing is done on drug release and content.
- Ideal formulations don't change in release or lose much of their drug content.

4. Pharmacokinetic and Pharmacodynamic Research in Vivo

These investigations validate how well the medication works within the body.

A. Pharmacokinetic Research (Improving Bioavailability)

What makes it significant?

- Calculates the amount of drug that enters the bloodstream.
- Calculates the absorption rate, half-life (T1/2), and maximum plasma concentration (Cmax). □

How Do You Do It?

1. Metformin-loaded SLMs are administered to animal models, such as rats and rabbits.
2. Blood samples are taken at various intervals (0, 2, 6, 12, 24 hours).
3. HPLC or LC-MS are used to measure the amount of metformin in plasma.

Anticipated outcomes:

Over time, higher plasma levels → Verify sustained release. A longer half-life (T1/2) results in a lower frequency of doses.

Reduced peak concentration (Cmax) → Reduces adverse effects (diarrhea, nausea).

B. Pharmacodynamic Research (Efficacy in Diabetes Management) What makes it significant?

- Assesses the effectiveness of sustained-release Metformin in regulating blood sugar. How Do You Do It?

1. Streptozotocin-induced rats are used as diabetic animal models.
2. Before and after the drug is administered, blood glucose levels are measured.
3. Glucose tolerance tests (GTT) evaluate long-term glucose regulation.

Anticipated outcomes:

☑Consistent glucose decrease over time → Verifies successful extended release. Glycemic control is superior to that of immediate-release Metformin.

Application and Advantages of Solid Lipid Microparticles (SLMs)-Based Metformin Formulation:

Solid lipid microparticles (SLMs) loaded with metformin have several benefits over traditional formulations, especially when it comes to better patient compliance, less gastrointestinal (GI) side effects, and controlled blood glucose regulation. Let's dissect these:

1. Regulated Blood Sugar

A. How Is Blood Sugar Controlled by Metformin?

- By activating the AMPK enzyme, metformin reduces the liver's production of glucose, which lowers blood sugar.
- Increasing muscle insulin sensitivity aids in the more effective absorption of glucose by cells.
- Lowering post-meal sugar spikes by decreasing intestinal glucose absorption.

B. How Do SLMs Increase the Effectiveness of Metformin? Sustained Release for Long-Lasting Effect:

- Regular Metformin needs several daily doses due to its short half-life (4-6 hours).
- SLMs offer a sustained release, which improves glycemic control by guaranteeing constant plasma levels for 12 to 24 hours.

Prevents Variations in Blood Sugar

- SLMs maintain stable blood levels, avoiding hypoglycemia (low blood sugar) and postprandial spikes.
- immediate-release metformin causes rapid absorption, resulting in high plasma levels initially, followed by a sharp decline.

Better Absorption in the Intestine:

- SLMs increase bioavailability, which means that lower doses may be required for the same effect.
- they also improve drug solubility and permeability, which results in improved absorption.

Key Results:
- Blood sugar levels that are more stable
- A decreased chance of hypoglycemia or hyperglycemia
- Improved long-term management of diabetes

2. Improved Patient Complience

A. What Causes Patients to Have Trouble Taking Metformin Regularly?

The multiple daily doses and high dose requirement (500–2000 mg/day) of metformin result in:
- Poor medication adherence because of frequent dosing.
- Inadequate glycemic control due to missed doses.
- Patients stop using it because of unpleasant side effects like diarrhea, bloating, and nausea.

B. How Do SLMs Enhance Adherence?

Daily Dosage Once
- Because SLMs release metformin gradually, a single daily dose rather than two or three doses per day is possible.
- Higher adherence results from more convenient, less frequent dosing.

Increased Tolerability
- Because of its high local concentration in the gut, conventional metformin irritates the stomach.
- SLMs reduce nausea and gastric irritation by delivering controlled drug release.

More Convenient Management
- Large doses of extended-release tablets are not necessary.
- Simpler preparation into tablets, suspensions, or capsules.

3 . Lessening of GI (gastrointestinal) adverse effects

A. Why Do GI Side Effects Occur With Metformin?

- Diarrhea is one of the GI side effects of metformin that approximately 30% of users
- experience. Metal taste (unpleasant for many patients).
- Bloating and nausea (caused by a high local drug concentration in the stomach).

Treatment discontinuation is frequently the result of these side effects.

B. In what ways do SLMs lessen gastrointestinal side effects?

- Stops Drugs from Building Up Quickly in the Stomach.
- SLMs release Metformin gradually, guaranteeing a slow, controlled release and less irritation.
- conventional Metformin dissolves quickly, resulting in a high local concentration in the gut, irritating the stomach lining.

Improved Intestine Absorption:

- SLMs increase the absorption of metformin, which means that less of the drug is left in the gut unabsorbed, which lessens bloating and diarrhea.

Bypass the Harsh Stomach Environment:

- SLMs improve stability and decrease degradation by shielding metformin from acidic stomach conditions.

Challenges and Future Pprespective of Metformin- Loaded Solid Lipid Microparticles (SLMs):

Even though solid lipid microparticles (SLMs) have a lot of potential for formulations of Metformin that release the medication over an extended period of time, there are still issues that must be resolved before they can be used extensively in clinical settings. Let's look at these problems and consider potential improvements.

1. Difficulties in Growing Production

A. Manufacturing Difficulties Challenge:

- Because of their variable particle size, drug entrapment efficiency, and stability issues, SLMs are difficult to produce on an industrial scale.
- Exact control over formulation parameters is necessary for high-energy processes (such as spray drying, microemulsion, and high shear homogenization).
- Problems with reproducibility occur, resulting in differences from batch to batch.

Why is this an issue?

- The kinetics of drug release may be impacted by irregular particle size.
- Pharmaceutical companies find it challenging to invest in SLM-based Metformin due to higher production costs.

Potential Remedies:

- Scalable technique optimization (e.g., spray drying is preferred for large-scale production).
- Utilizing sophisticated automation and process control to guarantee consistent drug loading and particle size.
- Techniques for nanoparticle engineering (like microfluidics) to improve reproducibility.

2. Lipid-Based Formulations: Regulatory Considerations

A. Barriers to New Drug Delivery Systems in Regulation

Challenge:

- SLMs need a thorough regulatory review because they are regarded as a novel drug delivery system.
- Because there are no established standards for lipid-based microparticles, the FDA and EMA have a lengthy approval process.
- Thorough research is required on matters pertaining to toxicity, biocompatibility, and long-term safety.

Why is this an issue?

- Before being marketed, SLM formulations need to show that they are bioequivalent to currently available Metformin XR products.
- To make sure lipid excipients don't have negative long-term effects, toxicological research is necessary.
- Studies on stability and degradation must demonstrate that the formulation maintains its efficacy over time.

Possible remedies include:

- Using FDA-approved excipients to expedite approval procedures.
- Preclinical and clinical trials to demonstrate safety, efficacy, and regulatory compliance.
- creating standardized testing procedures for formulations containing lipids.

3. Possibility of Using Other Antidiabetic Drugs in Combination Therapy

A. The Importance of Combination Treatment

The challenge:

- In order to achieve the best blood sugar control, many patients with Type 2 Diabetes Mellitus (T2DM) need to take multiple medications.
- Other antidiabetic medications, like:
  - SGLT2 inhibitors (e.g. Empagliflozin)
  - DPP-4 inhibitors (e.g. sitagliptin)
  - GLP-1 receptor agonists (e.g. liragltutide)
  - Sulfonylureas (e.g. Glimepiride)

Why is this an issue?

- Metformin-loaded SLMs must be designed to co-deliver multiple medications while preserving sustained release properties.
- current combination therapy necessitates multiple pills, which lowers patient compliance.

Potential solutions.

- SLM formulations with dual-drug loading, which enable combination therapy in a single-dose formulation.
- Lipid-based nanocarriers for improved drug compatibility, such as lipid-polymer hybrids and nanostructured lipid carriers.
- Advanced drug layering methods that enable sequential drug release, such as multi- compartment SLMs.

4. Prospects for the Future

A. Progress in Drug Delivery Using Lipids

- Nanostructured lipid carriers (NLCs):Hybrid systems that combine liquid and solid lipids to enhance drug loading and stability.
- Lipid-polymer hybrid nanoparticles (LPHNs): These nanoparticles combine the controlled release properties of polymers with lipid biocompatibility.
- Microsphere-based injectable formulations: These lessen the need for oral dosing for long-acting injectable Metformin formulations.

B. The Use of Personalized Medicine to Treat Diabetes

- SLM formulations that are tailored to the needs of each patient (e.g., extended release for blood sugar control at night).
- Intelligent medication delivery systems that release metformin when necessary in response to glucose levels.

Conclusion

The creation of metformin sustained-release solid lipid microparticles (SLMs) presents a viable way to get around the drawbacks of traditional formulations. Metformin, a medication commonly used to treat type 2 diabetes mellitus (T2DM), has drawbacks like short half-life, poor bioavailability, and gastrointestinal side effects, which

make patients less likely to take it as prescribed. By increasing drug stability, extending release, and lowering dosage frequency,

SLM-based drug delivery offers an answer that eventually boosts therapeutic efficacy.

By using diffusion and erosion mechanisms, SLMs provide controlled drug release, minimizing blood glucose fluctuations and lowering the possibility of gastrointestinal discomfort. To achieve the best encapsulation efficiency and long-lasting drug action, the right lipids, surfactants, and preparation methods must be chosen. Assessment using both in vitro and in vivo research validates that SLMs are effective in enhancing the pharmacokinetic profile of metformin.

Notwithstanding these developments, there are still issues with combination therapy formulation optimization, regulatory approvals, and large-scale manufacturing. To further improve metformin's therapeutic benefits, future studies should concentrate on lipid-polymer hybrids, nanostructured lipid carriers (NLCs), and personalized medicine techniques. All things considered, sustained-release SLMs offer a more patient-friendly and efficient therapeutic option, marking a major advancement in the management of diabetes.

References

1. Almeida, A. J., & Souto, E. (2007). Solid lipid nanoparticles as a drug delivery system for peptides and proteins. *Advanced Drug Delivery Reviews, 59*(6), 478-490. https://doi.org/10.1016/j.addr.2007.04.007.
2. Basha, R. H., & Sankaranarayanan, C. (2014). Development and characterization of metformin-loaded solid lipid nanoparticles for sustained drug release. *Journal of Pharmaceutical Sciences and Research, 6*(6), 210-218.
3. Das, S., Chaudhury, A., & Roy, D. (2012). Nanoparticle-based sustained release formulation of metformin for improved diabetes therapy. *International Journal of Nanomedicine, 7*, 4355-4370. https://doi.org/10.2147/IJN.S32874
4. Dubey, V., Mohan, P., & Mahor, S. (2011). Novel solid lipid microparticles for controlled delivery of metformin: In-vitro and in-vivo evaluation. *Drug Development and Industrial Pharmacy, 37*(8), 980-990. https://doi.org/10.3109/03639045.2011.573586
5. Jain, S., Jain, A., Gupta, Y., & Jain, S. K. (2010). Solid lipid nanoparticles bearing temozolomide for brain targeting. *Journal of Controlled Release, 127*(2), 126-132. https://doi.org/10.1016/j.jconrel.2008.12.018
6. Müller, R. H., Radtke, M., & Wissing, S. A. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. *Advanced Drug Delivery Reviews, 54*(Suppl 1), S131-S155. https://doi.org/10.1016/S0169-409X(02)00118-7
7. Pandey, R., Khuller, G. K. (2005). Solid lipid nanoparticle-based inhalable sustained drug delivery system against experimental tuberculosis. *Journal of Antimicrobial Chemotherapy, 55*(1), 430-435. https://doi.org/10.1093/jac/dki046
8. Saraf, S., Jain, H., & Jain, S. (2019). A novel sustained release formulation of metformin solid lipid microparticles for improved bioavailability. *International Journal of Pharmaceutics, 560*, 173-182. https://doi.org/10.1016/j.ijpharm.2019.01.045
9. Shah, R., Eldridge, D., Palombo, E., & Harding, I. H. (2014). Development and optimization of solid lipid nanoparticles for enhancing oral bioavailability of poorly water-soluble drugs. *Journal of Pharmaceutical Sciences, 103*(12), 4111-4120. https://doi.org/10.1002/jps.24191
10. Uner, M., & Yener, G. (2007). Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. *International Journal of Nanomedicine, 2*(3), 289-300.
11. Umeyor, C. E., Kenechukwu, F. C., & Ogbonna, J. D. N. (2011). *Preliminary studies on the functional properties of gentamicin in SRMS-based solid lipid microparticles.*
12. Nanjwade, B. K., Patel, D. J., Parikh, K. A., & Nanjwade, V. K. (2011). *Development and characterization of solid lipid microparticles of highly insoluble drug sirolimus for oral delivery.* Journal of Bioequivalence & Bioavailability.
13. Umeyor, C. E., Kenechukwu, F. C., & Uronnachi, E. M. (2012). *Solid lipid microparticles (SLMs): An effective lipid-based technology for controlled drug delivery.* American Journal of PharmTech Research.
14. Barua, S., Kim, J. T., Hong, S. C., & Yoo, S. Y. (2017). *Absorption study of genistein using solid lipid microparticles and nanoparticles: Control of oral bioavailability by particle sizes.* Biomolecules & Therapeutics.
15. Gugu, T. H., Chime, S. A., & Attama, A. A. (2015). *Solid lipid microparticles: An approach for improving oral bioavailability of aspirin.* Asian Journal of Pharmaceutical Sciences.
16. Domb, A. J., & Nahum, V. (2022). *Solid lipid microspheres decorated nanoparticles as drug carriers.* International Journal of Pharmaceutics.
17. Momoh, M. A., Kenechukwu, F. C., & Attama, A. A. (2013). *Formulation and evaluation of novel solid lipid microparticles as a sustained release system for the delivery of Metformin hydrochloride.* Drug Delivery Journal.
18. Kenechukwu, F. C., Momoh, M. A., & Nnamani, P. O. (2015). *Solid lipid micro-dispersions (SLMs) based on PEGylated solidified*

reverse micellar solutions (SRMS): A novel carrier system for gentamicin. Drug Delivery Journal.

19. Bertoni, S., Albertini, B., Facchini, C., Prata, C., & Passerini, N. (2019). *Glutathione-loaded solid lipid microparticles as an innovative delivery system for oral antioxidant therapy.* Pharmaceutics.

20. El-Kamel, A. H., Al-Fagih, I. M., & Alsarra, I. A. (2007). *Testosterone solid lipid microparticles for transdermal drug delivery: Formulation and physicochemical characterization.* Journal of Microencapsulation.

21. Krebs-Brown, A., Brand, K.M.G., & Nogueira Filho, M.A.F. (2024). *Bioequivalence of Related GelShield® Sustained-Release Formulations of Metformin: A Pooled Pharmacokinetic Analysis.* Clinical herapeutics, Elsevier.

22. Pena, E., Inatti, A., & Taly, A. (2024). *Bioequivalence of Two Formulations of Metformin Hydrochloride 1000 mg XR Tablets, Fasting Condition in Healthy Adult Subjects.* Journal of Biosciences and Medicine.

23. Bhattiprolu, A.K., Kollipara, S., & Boddu, R. (2024). *A physiologically based biopharmaceutics model to describe complex and saturable absorption of Metformin: Justification of dissolution specifications for extended release formulation.* AAPS PharmSciTech, Springer.

24. Kosuru, S.K., Mounika, G., & Jyoshna, R. (2024). *Formulation and Evaluation of Metformin Controlled Release Tablets Using Tamarind Seed Gum Powder as a Natural Polymer.* Journal of Clinical and Pharmaceutical Research.

25. Bharathi Priya, K., Pillai, K.K., & Nalini, C.N. (2024). *Formulation and characterization of 5-fluorouracil and Metformin biodegradable nanospheres for treating colon cancer.* Future Journal of Pharmaceutical Sciences, Springer.
26. Saini, V., Mata Espinosa, D., Pandey, A., & Dighe, V. (2024). *Antimycobacterial Activity of Solid Lipid Microparticles Loaded with Ursolic Acid and Oleanolic Acid: In Vitro, In Vivo, and Toxicity Assessments.* Microorganisms, MDPI.

27. Mancer, D., Agouillal, F., & Daoud, K. (2024). *Design and optimization of metformin solid lipid microparticles for topical application.* European Journal of Lipid Science and Technology, Wiley Online Library.
28. Momoh, M.A., Kenechukwu, F.C., & Attama, A.A. (2013). *Formulation and evaluation of novel solid lipid microparticles as a sustained release system for the delivery of Metformin hydrochloride.* Drug Delivery, Taylor & Francis.

29. Mancer, D., Agouillal, F., & Daoud, K. (2024). *Design and optimization of metformin solid lipid microparticles for topical application.* European Journal of Lipid Science and Technology, Wiley.

30. Kenechukwu, F.C., Nnamani, D.O., & Duhu, J.C. (2022). *Potential enhancement of metformin hydrochloride in solidified reverse micellar solution-based PEGylated lipid nanoparticles targeting therapeutic efficacy in diabetes management.* Heliyon, Cell Press.

31. Sharma, N., Rana, S., & Shivkumar, H.G. (2013). *Solid lipid nanoparticles as a carrier of Metformin for transdermal delivery.* International Journal of Drug Delivery.

32. Momoh, M.A., Ugwu, C.E., & Jackson, T.C. (2017). *Sustained release formulation of Metformin-solid dispersion based on Gelucire 50/13-PEG4000: An in vitro study.* International Journal of Pharmaceutics.

33. Ngwuluka, N.C., Kotak, D.J., & Devarajan, P.V. (2017). *Design and characterization of Metformin-loaded solid lipid nanoparticles for colon cancer treatment.* AAPS PharmSciTech, Springer.

34. Mahajan, N., Gangane, P.S., & Kadam, M.M. (2018). *Design and formulating gliclazide solid dispersion immediate release layer and Metformin sustained release layer in bilayer tablet for the effective postprandial management of diabetes mellitus.* International Journal of Pharmaceutical Sciences.

35. Verma, A., Sahu, A.K. (2016). *Optimization of chitosan and eudragit-based gastroretentive controlled release multiparticulate system for bioavailability enhancement of Metformin HCl.* Journal of Pharmaceutical Investigation, Springer.
36. Rafiee, M.H., & Rasool, B.K.A. (2024). *Drug Delivery System and its Extensive Therapeutic Applications in Diabetes.* Advanced Pharmaceutical Bulletin.

37. Mancer, D., Agouillal, F., & Daoud, K. (2024). *Design and optimization of Metformin solid lipid microparticles for topical application.* European Journal of Lipid Science and Technology, Wiley.

38. Sahu, A.K., & Verma, A. (2016). *Development and statistical optimization of chitosan and eudragit-based gastroretentive controlled-release multiparticulate system for bioavailability enhancement of Metformin HCl.* Journal of Pharmaceutical Investigation, Springer.

39. Polizzi, A., Tartaglia, G.M., & Amato, M. (2023). *Local delivery and controlled-release drug systems: A new approach for the*

clinical treatment of periodontitis therapy. Pharmaceutics, MDPI.

40. Kenechukwu, F.C., & Nnamani, D.O. (2023). *PEGylated lipid nanocontainers tailored with sunseed-oil- based solidified reverse micellar solution for enhanced pharmacodynamics and pharmacokinetics of Metformin.* Journal of Drug Delivery Science and Technology, Springer.

41. Rafiee, M.H., & Rasool, B.K.A. (2024). *Drug Delivery System and its Extensive Therapeutic Applications in Diabetes.* Advanced Pharmaceutical Bulletin.

42. Mancer, D., Agouillal, F., & Daoud, K. (2024). *Design and optimization of Metformin solid lipid microparticles for topical application.* European Journal of Lipid Science and Technology, Wiley.

43. Polizzi, A., Tartaglia, G.M., & Amato, M. (2023). *Local delivery and controlled release drug systems: A new approach for the clinical treatment of periodontitis therapy.* Pharmaceutics, MDPI.

44. Kenechukwu, F.C., & Nnamani, D.O. (2023). *PEGylated lipid nanocontainers tailored with sunseed-oil- based solidified reverse micellar solution for enhanced pharmacodynamics and pharmacokinetics of Metformin.* Journal of Drug Delivery Science and Technology, Springer.

45. Mirazi, N., Khazaei, A., & Hosseini, A. (2015). *A comparative study on the effect of Metformin and Metformin-conjugated nanotubes on blood glucose homeostasis in diabetic rats.* European Journal of Drug Metabolism and Pharmacokinetics, Springer.

46. Rafiee, M.H., & Rasool, B.K.A. (2024). *Drug Delivery System and its Extensive Therapeutic Applications in Diabetes.* Advanced Pharmaceutical Bulletin.

47. Polizzi, A., Tartaglia, G.M., & Amato, M. (2023). *Local delivery and controlled release drugs systems: A new approach for the clinical treatment of periodontitis therapy.* Pharmaceutics, MDPI.

48. Mancer, D., Agouillal, F., & Daoud, K. (2024). *Design and optimization of Metformin solid lipid microparticles for topical application.* European Journal of Lipid Science and Technology, Wiley.

49. Explores the stability challenges and formulation techniques of Metformin SLMs.
50. Rafiee, M.H., & Rasool, B.K.A. (2021). *An overview of microparticulae drug delivery systems and their extensive therapeutic applications in diabetes.* Advanced Pharmaceutical Bulletin.